Milestone represents a major advance in expanding the rareSHIFT™ discovery program and patient datamine to develop drugs for shared therapeutic mechanisms.

BOSTON, MASSACHUSETTS. February 27, 2026 -- Unravel Biosciences, Inc., ("Unravel"), a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform, today announced that the rareSHIFT™ discovery program has reached the milestone of working with patients to identify new drug targets and therapeutic mechanisms representing 100 unique disorders.

This large scale primary patient data is instrumental in uncovering shared pathways and drug targets. Starting with patient data and applying AI-based network analysis algorithms has already resulted in prioritization of select drug candidates to treat many disorders with shared biological mechanisms, even in patients with different symptoms or causes.

“Our primary patient RNA datamine has revealed just how different patient responses can be and the importance of a patient-centric approach. The variability among patients, and even within a patient over time, can be substantial. It’s absolutely critical that each patient become the center of focus of developing therapeutics,” said Neal Muni, MD, MSPH, Chief Medical Officer.

rareSHIFT™ is a patient-driven drug discovery program that collects patient and matched healthy control RNA from participants around the globe. Since initiating the program in 2024, Unravel has generated a rapidly expanding datamine of primary human RNA transcriptomes encompassing approximately 3,000 samples, from 100 disorders, from a diverse set of participants from over 30 countries. Patient and control datasets are transformed using proprietary AI algorithms into Living Molecular Twins™ (LMTs), digitized versions of patients made by Unravel’s computational AI platform, BioNAV™.

LMTs enable rapid identification of drug targets, disease mechanisms, and new or existing small molecules for the treatment of any disorder, providing a clinical preview of treatment outcomes for complex, dynamic processes like aging. Unravel has used LMTs for internal and partnered drug development from discovery to clinical use, including two lead assets, one of which is now in Phase I clinical trials for Rett and Pitt Hopkins syndromes. Unravel has applied LMTs to a variety of disorders, including neurodevelopmental and neurodegenerative disorders, muscle dystrophies and paraplegias, long COVID, patients with multiple disorders, and even undiagnosed disorders.

“The unique scale and diversity of Unravel’s patient and healthy control datamine has transformed how we approach our commercial development strategy,” said Richard Novak, PhD, Chief Executive Officer. “We can now accurately predict clinical outcomes for individual patients for any intervention, allowing us to predict preclinical and clinical trajectories for each molecule, optimize clinical trial design, and build commercially-valuable markets for our drug candidates based on patient outcome rather than a diagnosis.”

About Unravel  Biosciences, Inc.

Unravel Biosciences is a clinical-stage therapeutics company that integrates AI systems biology computation with rapid clinical validation of discovered targets, leading to four clinical trials starting in 2026.  Unravel leverages its proprietary BioNAV™ platform and primary transcriptomics data to create Living Molecular Twins of real patients that can be used to predict therapeutic response. This enables target and drug discovery, preclinical screening, patient stratification, and clinical validation to find treatments for complex diseases using a systematic, data-driven approach called Predictable Medicine™.

Unravel's platform discovered RVL002, a first-in-class small molecule that targets mitochondrial metabolism and has multiple clinical applications, including neurodegenerative and metabolic disorders, and identified RVL069, a molecule that targets a novel mechanism to treat dystonias and demyelination disorders. The rareSHIFT™ program provides platform and proprietary datamine access to foundation and biotech partners to accelerate and clinically derisk therapeutics. www.unravel.bio and www.rareshift.org